Eastern Congo Starts New Ebola Treatment Trial Amid Ongoing Health Challenges
New clinical trial offers hope against Ebola.
Residents in eastern Democratic Republic of the Congo are expressing renewed hope after the launch of a clinical trial evaluating potential treatments for the ongoing Ebola outbreak. The study began in early July at the Evangelical Medical Centre in Bunia, the epicentre of the outbreak, where researchers are testing experimental therapies aimed at improving survival rates among infected patients. The initiative comes as healthcare workers continue battling one of the country's most serious public health emergencies.
The outbreak is caused by the Bundibugyo strain of the Ebola virus, a less common variant for which there are currently no approved vaccines or specific treatments. According to the World Health Organization (WHO), more than 1,400 people have been infected and at least 438 have died. The trial is assessing the effectiveness of the antiviral drug remdesivir, the experimental antibody treatment MBP134, and a combination of both, with researchers monitoring patients for 28 days after treatment begins.
The WHO-supported research is being conducted in collaboration with the Democratic Republic of the Congo's National Institute for Biomedical Research (INRB), the University of Oxford, the Institute of Tropical Medicine in Antwerp, and other international health partners. The first phase of the study is limited to confirmed Ebola patients receiving care at specialized treatment centres. A second phase is expected to include healthcare workers, close contacts of infected patients, and other individuals considered to be at high risk of exposure.
Also Read: Mumbai Records Over 250 mm Rainfall, IMD Issues Red Alert Amid Flooding Fears
For many residents of Bunia, the trial represents a significant source of optimism after weeks of fear and uncertainty. Ebola survivor Gladys Munguro, who recently recovered after treatment, said she witnessed several patients lose their lives while receiving care and hopes the experimental therapies will improve survival for future patients. Other residents also described the study as an important step toward controlling the outbreak and reducing the devastating impact of the disease on local communities.
Despite the optimism, health officials acknowledge that major challenges continue to hamper the response. Community mistrust of medical interventions remains widespread, with some residents expressing concerns about participating in clinical research. Overcrowded treatment centres, delayed medical consultations, and ongoing insecurity in conflict-affected areas have further complicated efforts to contain the virus and provide timely care to those infected.
Authorities say the clinical trial is currently available only at Bunia's Evangelical Medical Centre but plan to expand it to additional locations once security conditions permit. Public health experts believe the research could continue for three to six months, depending on the progression of the outbreak. Officials hope the findings will not only improve treatment for the current epidemic but also strengthen global preparedness against future outbreaks caused by the Bundibugyo strain of the Ebola virus.
Also Read: Calls Targeting Trump Echo During Khamenei Funeral Ceremony, Escalating US-Iran Tensions
